New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology
June 23 2016 - 7:03AM
Business Wire
Masimo (NASDAQ: MASI) and SunTech Medical, a Halma (LSE:HLMA)
company, jointly announced today the integration of Masimo SET®
pulse oximetry technology into SunTech’s CT40, a next generation
spot-check vital signs device.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160623005340/en/
Masimo Signal Extraction Technology (SET®) Measure-through
Motion and Low Perfusion™ pulse oximetry measures oxygen saturation
(SpO2), pulse rate, and perfusion index. Masimo SET® has been shown
to significantly reduce false alarms and accurately monitor for
true alarms1,2 and is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around
the world.
The SunTech CT40 is an ideal, affordable solution for
clinical-grade spot-check measurements of blood pressure,
temperature and pulse oximetry in hospitals and clinics. Ambulatory
care, long-term care and low-acuity hospital departments can easily
implement this versatile, user-friendly vital signs device that
offers both advanced features and digital connectivity. The modular
design allows clinicians to easily make adaptations to the device
while in the field, adding thermometry, SpO2 and Wi-Fi as needed.
Other advanced features include the ability to transmit measurement
data directly from the device, in accordance with HL7 messaging
protocols, as well as BP Averaging Mode—an increasingly important
component of accurate blood pressure measurement, as evidenced by
the recently published SPRINT Study from the National Institutes of
Health (NIH), which specified that a mean of three office BP
measurements would be used to establish target BPs for Standard
Group participants.3
“Both SunTech and Masimo share industry-leading technologies
within our respective areas of expertise,” said Kenny Andersen, VP
of Strategic Product Development at SunTech Medical. “Partnering
with them on our next-generation vital signs platform is a very
natural strategy. Masimo SET pulse oximetry is the benchmark for
clinical performance, just as SunTech Advantage technology is for
blood pressure. We look forward to a long and successful
partnership.”
Rick Fishel, Masimo’s President of Worldwide OEM Business and
Strategic Development, stated, “SunTech Medical is a recognized
global leader and worldwide supplier of non-invasive blood pressure
measurement technology. Combining best-in-class measurement
technologies that provide superior performance, accuracy, and
affordability, in flexible and cost effective monitors, supports
our organizations’ mutual vision to offer solutions that help
clinicians improve patient outcomes and reduce the cost of
healthcare delivery. We are very pleased to partner with SunTech
Medical and that Masimo SET pulse oximetry is the preferred pulse
oximetry offering in the highly versatile and cost-effective
SunTech CT40 monitor.”
The SunTech CT 40 with Masimo SET® technology has a CE Mark. It
is not FDA cleared and is not available for sale in the United
States.
@MasimoInnovates | #Masimo
1.
Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of
Three New-Generation Pulse Oximeters during Motion and Low
Perfusion in Volunteers" .J Clin Anesth. 2012 Aug;24(5):385-91.
2.
Taenzer, Andreas H.; Pyke, Joshua B.;
McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry
Surveillance on Rescue Events and Intensive Care Unit Transfers: A
Before-and-After Concurrence Study." Anesthesiology, February 2010,
Vol. 112, Issue 2.
3.
The SPRINT Study Research Group; The design and rationale of a
multi-center clinical trial comparing two strategies for control of
systolic blood pressure: The Systolic Blood Pressure Intervention
Trial (SPRINT); Clin Trials; October 2014; 11(5): 532-546.
About SunTech Medical
SunTech Medical, a Halma company, has been the preeminent
supplier of clinical-grade blood pressure monitoring products and
technologies for nearly 30 years. More than 75 companies trust
SunTech Medical's OEM non-invasive blood pressure solutions for
their patient monitoring needs. SunTech Medical produces the
leading cardiac stress test blood pressure monitor and is the
world's foremost manufacturer of ambulatory blood pressure
monitoring products. SunTech Medical also offers solutions for
in-office blood pressure monitoring as well as a complete line of
blood pressure cuffs designed for general and specific
applications.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care by taking noninvasive
monitoring to new sites and applications. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world.
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more
recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index
(ORI™), in addition to SpO2, pulse rate, and perfusion index (PI).
In 2014, Masimo introduced Root®, an intuitive patient monitoring
and connectivity platform with the Masimo Open Connect™ (MOC-9™)
interface. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7™ wearable patient
monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at
www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential benefits of Masimo’s SET® pulse oximetry
technology into SunTech’s CT 40. These forward-looking statements
are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are
difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely
from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique
noninvasive measurement technologies, including Masimo’s SET® pulse
oximetry technology, contribute to positive clinical outcomes and
patient safety; risks related to our belief that Masimo noninvasive
medical breakthroughs provide cost-effective solutions with
comparable accuracy and unique advantages, including: immediate and
continuous results that enable earlier treatment without causing
invasive trauma in all patients and in every clinical situation; as
well as other factors discussed in the "Risk Factors" section of
our most recent reports filed with the Securities and Exchange
Commission ("SEC"), which may be obtained for free at the SEC's
website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All
forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date. We
do not undertake any obligation to update, amend or clarify these
statements or the "Risk Factors" contained in our most recent
reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the
applicable securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160623005340/en/
MasimoIrene Paigah,
858-859-7001irenep@masimo.comorSunTech MedicalElliott
Holloway, 919-654-2366eholloway@suntechmed.com
Halma (LSE:HLMA)
Historical Stock Chart
From Apr 2024 to May 2024
Halma (LSE:HLMA)
Historical Stock Chart
From May 2023 to May 2024